复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

32.850

-0.250

-0.76%

最高--	最低--	成交量304.35万
今开--	昨收33.100	日振幅3.17%
总市值841.91亿	流通市值181.31亿	总股本25.63亿
成交额9,882万	换手率0.55%	流通股本5.52亿
市净率1.89	ROE--	每股收益2.15
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

Data provider: Ningxia XSRK Technology Limited

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"market":"HK","stockBase":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":32.85,"timestamp":1652774935015,"preClose":33.1,"halted":0,"volume":3043517,"delay":0,"change":-0.25,"changeRate":-0.007553,"floatShares":551940500,"shares":2562898545,"eps":2.150391,"lyrEps":2.150391,"pbRate":1.89,"psRate":1.75,"amount":98817454,"amplitude":0.031722,"volumeRatio":0.366881,"dividePrice":0.651767,"prevYearClose":34.35,"fiveDayClose":30,"twentyDayClose":32.95,"astockBrief":{"symbol":"600196","name":"复星医药","latestPrice":50.59341}},"adData":{"groupTypeList":[],"userSplitList":[]},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2236212453","title":"复星医药(02196)子公司汉霖制药获药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2236212453","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2236212453?lang=zh_CN&edition=full","pubTime":"2022-05-17 18:30","pubTimestamp":1652783422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司上海复宏汉霖生物制药有限公司(汉霖制药)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》(通知书编号：2022B02028、2022B02029)，汉霖制药关于汉曲优®(注射用曲妥珠单抗)变更生产场地、优化生产工艺及扩大制剂规模等补充申请获批准。本次变更后的生产场地已于2022年4月通过上海市药品监督管理局组织开展的药品生产质量管理规范符合性检查(即药品GMP符合性检查)。本次补充申请获批后，有利于进一步提高该药品的产能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/724764.html","is_publish_highlight":false},{"id":"2236212092","title":"复星医药(02196.HK)：汉霖制药关于汉曲优变更生产场地、优化生产工艺及扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2236212092","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2236212092?lang=zh_CN&edition=full","pubTime":"2022-05-17 18:28","pubTimestamp":1652783311,"startTime":"0","endTime":"0","summary":"格隆汇5月17日丨复星医药公告，近日，上海复星医药(集团)股份有限公司控股子公司上海复宏汉霖生物制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，汉霖制药关于汉曲优变更生产场地、优化生产工艺及扩大制剂规模等补充申请获批准。2021年度，汉曲优于中国境内的销售额约为人民币8.68亿元。　　截至公告日，除汉曲优外，于中国境内上市的曲妥珠单抗包括上海罗氏制药有限公司的赫赛汀。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/05/17182836655945.shtml","is_publish_highlight":false},{"id":"2236216003","title":"复星医药(600196.SH)子公司汉霖制药获药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2236216003","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2236216003?lang=zh_CN&edition=full","pubTime":"2022-05-17 17:25","pubTimestamp":1652779550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物制药有限公司(以下简称“汉霖制药”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》(通知书编号：2022B02028、2022B02029)，汉霖制药关于汉曲优®(注射用曲妥珠单抗)(以下简称“该药品”)变更生产场地、优化生产工艺及扩大制剂规模等补充申请(以下简称“本次补充申请”)获批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/724682.html","is_publish_highlight":false},{"id":"2235803952","title":"快讯｜复星医药与Kite Pharma同比例增资复星凯特，增资后持股比例不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2235803952","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2235803952?lang=zh_CN&edition=full","pubTime":"2022-05-16 14:24","pubTimestamp":1652682252,"startTime":"0","endTime":"0","summary":"财经网产经讯　复星医药公告显示，控股子公司复星医药产业与 Kite Pharma 签订协议，双方拟分别出资不超过 2,500 万美元对复星凯特进行同比例增资，认缴复星凯特等值新增注册资本。信息显示，截至公告日，复星凯特的注册资本为 17,900 万美元，其中：复星医药产业、Kite Pharma 分别持有复星凯特 50%的股权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-16/doc-imcwiwst7701604.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-16/doc-imcwiwst7701604.shtml","is_publish_highlight":false},{"id":"2235423246","title":"复星医药(02196.HK)向复星凯特增资最多2,500万美元等值人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2235423246","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2235423246?lang=zh_CN&edition=full","pubTime":"2022-05-16 09:28","pubTimestamp":1652664499,"startTime":"0","endTime":"0","summary":"复星医药  (600196.SH)公布，控股子公司复星医药产业拟出资不超过等值於2,500万美元的人民币现金，与Kite Pharma根据各自所持股权比例对复星凯特进行同比例增资。由於公司高级管理人员兼任复星凯特董事，复星凯特构成公司的关联方、本次投资构成关联交易。(na/da)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1184082&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2235926493","title":"上海复星医药（集团）股份有限公司第八届董事会第七十二次会议（临时会议）决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2235926493","media":"中国证券报-中证网","top":-1,"share":"https://www.laohu8.com/m/news/2235926493?lang=zh_CN&edition=full","pubTime":"2022-05-14 05:34","pubTimestamp":1652477642,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司第八届董事会第七十二次会议于2022年5月13日召开，全体董事以通讯方式出席了会议，本次会议的召开符合《中华人民共和国公司法》、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》的规定。本次关联交易经独立非执行董事事前认可后，提请本公司第八届董事会第七十二次会议审议。本次关联交易无需提请本公司股东大会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-14/doc-imcwipii9757878.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-14/doc-imcwipii9757878.shtml","is_publish_highlight":false},{"id":"2235149864","title":"复星医药拟携Kite Pharma合计增资复星凯特5000万美元 用于产品商业化和研发管线投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2235149864","media":"中国证券报·中证网","top":-1,"share":"https://www.laohu8.com/m/news/2235149864?lang=zh_CN&edition=full","pubTime":"2022-05-13 20:58","pubTimestamp":1652446680,"startTime":"0","endTime":"0","summary":"增资后，复星医药产业对复星凯特的持股比例保持不变，复星凯特仍为集团的合营企业。复星凯特主要从事肿瘤免疫细胞治疗产品的研发、生产和商业化，复星医药产业、Kite Pharma分别持有公司50%的股权。本次增资款项将主要用于复星凯特产品商业化和研发管线的投入。2021年，复星凯特实现营业收入4390万元，净利润亏损4.01亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202205132105058043c173&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202205132105058043c173&s=b","is_publish_highlight":false},{"id":"2235195913","title":"复星医药(02196)：复星医药产业拟出资不超2500万美元对复星凯特增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2235195913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2235195913?lang=zh_CN&edition=full","pubTime":"2022-05-13 19:10","pubTimestamp":1652440230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，公司审议通过关于参与对复星凯特生物科技有限公司增资的议案。公司同意控股子公司上海复星医药产业发展有限公司出资不超过等值于2500万美元的人民币现金与KP EU C.V.根据各自所持复星凯特生物科技有限公司的股权比例对复星凯特进行同比例增资。同时，同意授权公司管理层或其授权人士办理与本次投资相关的具体事宜，包括但不限于签署、修订并执行相关协议等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/723392.html","is_publish_highlight":false},{"id":"2235620811","title":"复星医药：复星医药产业拟与Kite Pharma对复星凯特同比例增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2235620811","media":"界面新闻","top":-1,"share":"https://www.laohu8.com/m/news/2235620811?lang=zh_CN&edition=full","pubTime":"2022-05-13 17:39","pubTimestamp":1652434740,"startTime":"0","endTime":"0","summary":"复星医药5月13日晚间公告，向控股子公司上海复星医药产业发展有限公司增资不超过2500万美元，与KPEUC.V.根据各自所持复星凯特生物科技有限公司的股权比例对复星凯特进行同比例增资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://finance.eastmoney.com/a/202205132378898672.html","is_publish_highlight":false},{"id":"2235498541","title":"复星医药：向控股子公司上海复星医药增资不超过2500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2235498541","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2235498541?lang=zh_CN&edition=full","pubTime":"2022-05-13 17:25","pubTimestamp":1652433900,"startTime":"0","endTime":"0","summary":"【复星医药：向控股子公司上海复星医药增资不超过2500万美元】复星医药公告， 向控股子公司上海复星医药产业发展有限公司增资不超过2500万美元，与KP EU C.V.根据各自所持复星凯特生物科技有限公司的股权比例对复星凯特进行同比例增资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2022051317255179ccd6c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2022051317255179ccd6c5&s=b","is_publish_highlight":false},{"id":"2235162918","title":"复星医药：向控股子公司上海复星医药增资不超过2500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2235162918","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2235162918?lang=zh_CN&edition=full","pubTime":"2022-05-13 17:24","pubTimestamp":1652433866,"startTime":"0","endTime":"0","summary":"复星医药公告， 向控股子公司上海复星医药产业发展有限公司增资不超过2500万美元，与KP EU C.V.根据各自所持复星凯特生物科技有限公司的股权比例对复星凯特进行同比例增资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-13/doc-imcwiwst7235375.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-13/doc-imcwiwst7235375.shtml","is_publish_highlight":false},{"id":"2235716235","title":"复星医药(600196.SH)拟携Kite Pharma向复星凯特合计增资不超5000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2235716235","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2235716235?lang=zh_CN&edition=full","pubTime":"2022-05-13 17:24","pubTimestamp":1652433857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，2022年5月13日，公司控股子公司复星医药产业与Kite Pharma 签订《合营合同之修正案(十一)》，双方拟分别出资不超过2500万美元(或不超过等值于2500万美元的人民币)对复星凯特进行同比例增资，认缴复星凯特等值新增注册资本。本次增资后，复星医药产业对复星凯特的持股比例保持不变(仍为50%)，复星凯特仍为集团的合营企业。公告显示，复星凯特主要从事肿瘤免疫细胞治疗产品的研发、生产和商业化。本次增资款项将主要用于复星凯特产品商业化和研发管线的投入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/723228.html","is_publish_highlight":false},{"id":"2235857149","title":"复星医药5月12日获南向资金加仓131.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2235857149","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2235857149?lang=zh_CN&edition=full","pubTime":"2022-05-13 09:31","pubTimestamp":1652405477,"startTime":"0","endTime":"0","summary":"5月12日, 南向资金增持复星医药131.10万股。截止当日收盘，港股通共持有复星医药18182.16万股，占流通股32.93%。复星医药近5个交易日上涨4.55%，港股通累计增持950.03万股；近20个交易日下跌8.77%，港股通累计增持875.53万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220513093710790e14cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220513093710790e14cc&s=b","is_publish_highlight":false},{"id":"2235508511","title":"上海复星医药（集团）股份有限公司关于职工监事选举结果的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2235508511","media":"中国证券报-中证网","top":-1,"share":"https://www.laohu8.com/m/news/2235508511?lang=zh_CN&edition=full","pubTime":"2022-05-13 05:39","pubTimestamp":1652391592,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2022年5月12日召开职工代表大会，会议选举任倩女士为本公司第九届监事会的职工监事。上海复星医药（集团）股份有限公司董事会二零二二年五月十二日任倩女士，1969年6月出生，现任本公司职工监事、监事会主席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-13/doc-imcwiwst7117038.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/roll/2022-05-13/doc-imcwiwst7117038.shtml","is_publish_highlight":false},{"id":"2235904287","title":"复星医药(02196.HK)子公司治疗细胞肿瘤新药临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2235904287","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2235904287?lang=zh_CN&edition=full","pubTime":"2022-05-13 02:21","pubTimestamp":1652379702,"startTime":"0","endTime":"0","summary":"复星医药  公布，控股子公司复星医药产业收到国家药品监督管理局关於同意FCN-159片用於组织细胞肿瘤治疗开展临床试验的通知书。该新药为集团自主研发的创新型小分子化学药物拟主要用於晚期实体瘤、I型神经纤维瘤、组织细胞肿瘤等的治疗。(de/d)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1183624&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2234247269","title":"复星医药(02196)重选任倩为第九届监事会的职工监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2234247269","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2234247269?lang=zh_CN&edition=full","pubTime":"2022-05-12 19:32","pubTimestamp":1652355120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，于2022年5月12日召开的职工代表大会重选现届职工监事任倩为第九届监事会的职工监事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/722677.html","is_publish_highlight":false},{"id":"2234924675","title":"创新研发驱动 复星医药(02196)入选“全球医药企业研发管线规模Top25”","url":"https://stock-news.laohu8.com/highlight/detail?id=2234924675","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2234924675?lang=zh_CN&edition=full","pubTime":"2022-05-12 19:22","pubTimestamp":1652354527,"startTime":"0","endTime":"0","summary":"从2021年到2022年，复星医药研发管线整体规模数量提升显著，较2021年度增长了127%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20220512/20220512190014_53274.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20220512/20220512190014_53274.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/722633.html","is_publish_highlight":false},{"id":"2234940759","title":"复星医药：FCN-159片药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2234940759","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2234940759?lang=zh_CN&edition=full","pubTime":"2022-05-12 17:49","pubTimestamp":1652348940,"startTime":"0","endTime":"0","summary":"财联社5月12日电，复星医药公告，FCN-159片用于组织细胞肿瘤治疗开展临床试验获国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://finance.eastmoney.com/a/202205122377412224.html","is_publish_highlight":false},{"id":"2234940452","title":"复星医药(600196.SH)：FCN-159片获批开展用于组织细胞肿瘤治疗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2234940452","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2234940452?lang=zh_CN&edition=full","pubTime":"2022-05-12 17:45","pubTimestamp":1652348728,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)公告，近日，公司控股子公司上海复星医药产业发展有限公司(“复星医药产业”)收到国家药品监督管理局关于同意FCN-159片(“该新药”)用于组织细胞肿瘤治疗开展临床试验的通知书。复星医药产业拟于条件具备后于中国境内开展该适应症的II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/722514.html","is_publish_highlight":false},{"id":"2234555991","title":"洞见生物医药|国产新冠口服药加速推进，相关概念股新华制药9连板！","url":"https://stock-news.laohu8.com/highlight/detail?id=2234555991","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2234555991?lang=zh_CN&edition=full","pubTime":"2022-05-12 09:15","pubTimestamp":1652318102,"startTime":"0","endTime":"0","summary":"5月11日一早，新冠特效药概念继续领涨，雅本化学、山河药辅20CM涨停，真实生物A股“朋友”华润双鹤、新华制药双双涨停，复星医药、诚达药业、君实生物均不同程度上涨。不过截止当日收盘，华润双鹤打开涨停，报收于35元/股，涨5.49%。自从加入真实生物“朋友圈”，并入新冠特效药概念，华润双鹤、新华制药连日来已经获得多个涨停。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202205_1/99e8e6b3-71c8-45dc-8d7b-b11abe18c47c.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202205_1/99e8e6b3-71c8-45dc-8d7b-b11abe18c47c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.finet.hk/newscenter/news_content/627c5f9653243c5cfa64a651","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.095},{"period":"1month","weight":-0.0478},{"period":"3month","weight":0.0529},{"period":"6month","weight":-0.1949},{"period":"1year","weight":-0.4405},{"period":"ytd","weight":-0.0437}],"websiteUrl":"http://www.fosunpharma.com","compareEarnings":[{"period":"1week","weight":0.0493},{"period":"1month","weight":-0.0425},{"period":"3month","weight":-0.1665},{"period":"6month","weight":-0.1863},{"period":"1year","weight":-0.2693},{"period":"ytd","weight":-0.1195}],"name":"复星医药","description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.038173},{"month":2,"riseRate":0.8,"avgChangeRate":0.038376},{"month":3,"riseRate":0.8,"avgChangeRate":0.077104},{"month":4,"riseRate":0.4,"avgChangeRate":0.050057},{"month":5,"riseRate":0.5,"avgChangeRate":0.033003},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.036716},{"month":7,"riseRate":0.555556,"avgChangeRate":0.024014},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.047676},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.003687},{"month":10,"riseRate":0.555556,"avgChangeRate":0.041049},{"month":11,"riseRate":0.5,"avgChangeRate":0.037483},{"month":12,"riseRate":0.6,"avgChangeRate":0.034121}],"exchange":"SEHK","nameEN":"FOSUN PHARMA","compareStock":{"symbol":"HSI","name":"恒生指数"}},"isWeiXinMini":false,"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情"}}